NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC lowered its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 2.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 872,537 shares of the company’s stock after selling 18,551 shares during the period. TimesSquare Capital Management LLC owned about 0.78% of NewAmsterdam Pharma worth $15,802,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NAMS. RA Capital Management L.P. raised its holdings in NewAmsterdam Pharma by 14.6% during the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock worth $207,544,000 after purchasing an additional 1,293,938 shares in the last quarter. Wellington Management Group LLP grew its stake in NewAmsterdam Pharma by 53.0% in the 1st quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company’s stock worth $72,504,000 after acquiring an additional 1,226,852 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of NewAmsterdam Pharma by 85.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,950,650 shares of the company’s stock worth $39,930,000 after acquiring an additional 900,650 shares during the period. Duquesne Family Office LLC raised its position in shares of NewAmsterdam Pharma by 178.4% in the 1st quarter. Duquesne Family Office LLC now owns 800,360 shares of the company’s stock worth $16,383,000 after buying an additional 512,825 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of NewAmsterdam Pharma by 20.7% in the 1st quarter. Alliancebernstein L.P. now owns 2,241,953 shares of the company’s stock valued at $45,893,000 after acquiring an additional 383,888 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Wells Fargo & Company initiated coverage on NewAmsterdam Pharma in a research report on Monday, August 25th. They set an “overweight” rating and a $45.00 price target on the stock. The Goldman Sachs Group began coverage on shares of NewAmsterdam Pharma in a report on Thursday, July 17th. They set a “neutral” rating and a $27.00 price target on the stock. Needham & Company LLC lifted their price target on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, HC Wainwright started coverage on shares of NewAmsterdam Pharma in a report on Monday, October 20th. They set a “buy” rating and a $52.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and an average target price of $44.30.

NewAmsterdam Pharma Stock Down 4.1%

Shares of NAMS stock opened at $38.26 on Thursday. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $41.47. The firm has a market capitalization of $4.31 billion, a P/E ratio of -18.66 and a beta of 0.05. The stock’s fifty day simple moving average is $32.30 and its 200 day simple moving average is $24.91.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. As a group, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper purchased 1,260 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were acquired at an average cost of $24.99 per share, with a total value of $31,487.40. Following the purchase, the director owned 3,027,864 shares in the company, valued at $75,666,321.36. This represents a 0.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the completion of the sale, the insider directly owned 119,302 shares of the company’s stock, valued at approximately $2,897,845.58. This trade represents a 29.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 226,342 shares of company stock valued at $5,748,019 in the last 90 days. 20.84% of the stock is currently owned by corporate insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.